| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
(S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid manufacturers
- PF-04991532
-
- $59.00
-
2026-05-11
- CAS:1215197-37-7
- Purity: 99.99%
- Supply Ability: 10g
|
| | (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid Basic information |
| Product Name: | (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid | | Synonyms: | (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid;6-[[(2S)-3-Cyclopentyl-1-oxo-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]propyl]amino]-3-pyridinecarboxylic acid;PF 04991532;3-Pyridinecarboxylic acid, 6-[[(2S)-3-cyclopentyl-1-oxo-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]propyl]amino]-;PF-04991532 >=98% (HPLC);PF 04991532,PF04991532;PF-04991532 | | CAS: | 1215197-37-7 | | MF: | C18H19F3N4O3 | | MW: | 396.36 | | EINECS: | | | Product Categories: | | | Mol File: | 1215197-37-7.mol |  |
| | (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid Chemical Properties |
| Boiling point | 646.5±55.0 °C(Predicted) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: soluble20mg/mL, clear | | pka | 3.55±0.10(Predicted) | | form | powder | | color | white to beige | | InChI | 1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1 | | InChIKey | GKMLFBRLRVQVJO-ZDUSSCGKSA-N | | SMILES | FC(F)(F)c1nc[n](c1)[C@@H](CC3CCCC3)C(=O)Nc2ncc(cc2)C(=O)O |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid Usage And Synthesis |
| Uses | PF 04991532 is a useful research chemical used as a hepatoselective glucokinase activator for treating type 2 diabetes mellitus. | | Biological Activity | PF-04991532 is a potent and hepatoselective glucokinase activator th at reduces mean daily glucose (MDG), fasting plasma glucose (FPG) and glucose excursion in humans. | | in vivo | A single dose of PF-04991532 increases the glucose infusion rate in order to maintain hyperglycemia. Despite the elevations in plasma triglycerides, surprisingly, hepatic triglycerides in rats dosed with 19 days of PF-04991532 are identical to vehicle treated GK rats. In an additional cohort treated for 28 days, identical hepatic lipid concentrations are observed between vehicle and rats dosed with PF-04991532 (Vehicle: 9.89±0.31; PF-04991532 100 mg/kg: 9.91±0.31). In rats treated with PF-04991532, there is increased expression of lipogenic gene expression such as acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), and fatty acid synthase (FAS)[1]. |
| | (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid Preparation Products And Raw materials |
|